Hyaluronan-Induced Stem Cell Differentiation for Progenitor Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pluripotent stem cells into mortal cells with proliferative capacity and lineage potential are limited, often resulting in heterogeneous or terminally differentiated cell populations, and rely on animal-derived factors that complicate bio-safety and scalability.
Innovation Solution
Culturing pluripotent stem cells in the presence of Hyaluronan (HA) to induce a mortal multi-lineage progenitor cell population with the capacity to form mesodermal, ectodermal, and endodermal lineages, which can be further differentiated by specific growth factors, mimicking the properties of adult mesenchymal stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If pluripotent stem cells are maintained in an undifferentiated state for self-renewal, then immortal self-renewal capacity is preserved, but tumour formation risk increases when transplanted
Solution Approach 1:
The patent applies preliminary action by pre-differentiating pluripotent stem cells into a transient amplifying progenitor state before transplantation. This intermediate differentiation step is performed in advance to reduce tumourigenicity while preserving proliferative capacity, allowing cells to be prepared with controlled properties prior to therapeutic use
Solution Approach 2:
The patent employs parameter changes by modifying the differentiation state of stem cells through controlled culture conditions. Cells are transitioned from a fully undifferentiated pluripotent state to a partially differentiated progenitor state, changing key parameters such as expression of pluripotency markers and proliferation potential to achieve the desired balance between safety and functionality
2Reliability
If stem cells are differentiated into functional cells for transplantation, then therapeutic value increases, but proliferative capacity is limited
Solution Approach 1:
The patent applies dynamics by creating a transient amplifying progenitor cell population that exhibits dynamic characteristics between fully undifferentiated and terminally differentiated states. These cells possess controlled proliferative capacity that can expand therapeutically relevant cell numbers while maintaining the potential to differentiate into functional cell types, providing a dynamic balance between expansion and differentiation
3Manufacturing precision
If conventional differentiation methods are used, then cell differentiation occurs, but heterogeneous or terminally differentiated populations are produced
Solution Approach 1:
The patent applies local quality by providing specific localized culture conditions that guide uniform differentiation toward a progenitor state. By controlling the microenvironment and signaling cues in the culture system, the method achieves homogeneous differentiation of cells into transient amplifying progenitors rather than heterogeneous mixed populations
Data Source
AI summary
A method for the differentiation of mammalian pluripotent stem (PS) cells into a mortal multi-lineage progenitor cell population is provided which comprises culturing the pluripotent stem cells in the presence of Hyaluronan (HA). The mortal multi-lineage progenitor cell population may be a population of mesenchymal stem cells. The mortal multi-lineage progenitor cell population may form cells of the mesodermal lineage, suitably osteoblasts. Alternatively, the mortal multi-lineage progenitor cell population may form cells of the endodermal lineage or of the ectodermal lineage, which may be neuronal progenitors.